T. Rowe Price Associates’s C4 Therapeutics CCCC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $189K | Buy |
|
|||||
|
2025
Q4 | $24K | Hold |
|
|||||
|
2025
Q3 | $28K | Hold |
|
|||||
|
2025
Q2 | $18K | Sell |
|
|||||
|
2025
Q1 | $62K | Hold |
|
|||||
|
2024
Q4 | $138K | Sell |
|
|||||
|
2024
Q3 | $2.23M | Buy |
|
|||||
|
2024
Q2 | $288K | Sell |
|
|||||
|
2024
Q1 | $17.3M | Sell |
|
|||||
|
2023
Q4 | $14.5M | Buy |
|
|||||
|
2023
Q3 | $4.07M | Sell |
|
|||||
|
2023
Q2 | $7.78M | Sell |
|
|||||
|
2023
Q1 | $9.03M | Sell |
|
|||||
|
2022
Q4 | $17.3M | Sell |
|
|||||
|
2022
Q3 | $26M | Sell |
|
|||||
|
2022
Q2 | $33M | Buy |
|
|||||
|
2022
Q1 | $106M | Buy |
|
|||||
|
2021
Q4 | $132M | Buy |
|
|||||
|
2021
Q3 | $177M | Buy |
|
|||||
|
2021
Q2 | $134M | Buy |
|
|||||
|
2021
Q1 | $77.6M | Buy |
|
|||||
|
2020
Q4 | $49.4M | Buy |
|